Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48448

UPID:
AL3B2_HUMAN

ALTERNATIVE NAMES:
Aldehyde dehydrogenase 8

ALTERNATIVE UPACC:
P48448; Q53Y98; Q8NAL5; Q96IB2

BACKGROUND:
The enzyme Aldehyde dehydrogenase family 3 member B2, alternatively named Aldehyde dehydrogenase 8, is pivotal in converting harmful medium and long chain aldehydes into safe fatty acids. This action is essential for the detoxification processes within the body.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Aldehyde dehydrogenase family 3 member B2 offers a promising avenue for developing new therapeutic approaches. Its critical role in neutralizing toxic aldehydes highlights its potential in disease prevention and treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.